Jody Corey-Bloom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jody Corey-Bloom has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Paul E. Gilbert
Department of Psychology San Diego State University San Diego California USA
5 shared publications- Jiang Du
Department of Radiology, University of California San Diego, La Jolla, USA
4 shared publications - Japleen Kaur
Department of Neurosciences University of California, San Diego San Diego California USA
3 shared publications - Krisha Bagga
UC San Diego
3 shared publications - Paul E. Gilbert
Department of Psychology, San Diego State University, San Diego, CA, USA
3 shared publications Ameera Haque
Neurosciences, UC San Diego La Jolla CA United States
2 shared publications
Latest Publications
- Open Access
- 25 October 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (4) , 949-955
Development and Validation of a Brief Fall Questionnaire ( FALL ‐ HD ) for Patients with Huntington's Disease
Background: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a mutation in the huntingtin gene on chromosome 4, leading to progressive cognitive decline, motor impairment, and functional disability. Falls represent the leading cause of nursing home placement in HD. Despite the significant clinical implications, validated instruments for fall assessment, including fall frequency, are lacking in HD. Objectives: To construct and evaluate the psychometric properties of a questionnaire for assessing fall status, including fall frequency, in ambulatory patients with HD. Methods: We developed a concise 3‐item questionnaire based on a comprehensive literature review and initial pilot study. We evaluated the responses of 107 HD gene‐positive participants in the main study. Reliability (test–retest, internal consistency) and validity (criterion, convergent, divergent) were assessed. Results: The FALL‐HD Questionnaire demonstrated reliability with a test–retest correlation coefficient of r = 0.85 and an internal consistency (Cronbach's alpha) of 0.71. Convergent validity was established using Spearman correlations with the UHDRS Total Motor Score ( r = 0.75, p < 0.001), Total Maximal Chorea Score ( r = 0.65, p < 0.001), and Total Functional Capacity ( r = 0.53, p < 0.001), in addition to Total Body Sway (TBS, r = 0.62, p < 0.001), a measure of postural stability from the BTrackS™ Balance System. Using ROC curves, the FALL‐HD outperformed (AUC = 0.90) existing measures of balance such as the Total Body Sway (AUC = 0.85), Chair Sit‐to‐Stand Test (AUC = 0.65) and Timed Up and Go (AUC = 0.58). Conclusions: The FALL‐HD is a brief, valid and reliable, screening instrument of fall status, including fall frequency, in ambulatory patients with HD.
- 25 October 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (4) , 949-955
Open AccessDevelopment and Validation of a Brief Fall Questionnaire ( FALL ‐ HD ) for Patients with Huntington's Disease
Background: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a mutation in the huntingtin gene on chromosome 4, leading to progressive cognitive decline, motor impairment, and functional disability. Falls represent the leading cause of nursing home placement in HD. Despite the significant clinical implications, validated instruments for fall assessment, including fall frequency, are lacking in HD. Objectives: To construct and evaluate the psychometric properties of a questionnaire for assessing fall status, including fall frequency, in ambulatory patients with HD. Methods: We developed a concise 3‐item questionnaire based on a comprehensive literature review and initial pilot study. We evaluated the responses of 107 HD gene‐positive participants in the main study. Reliability (test–retest, internal consistency) and validity (criterion, convergent, divergent) were assessed. Results: The FALL‐HD Questionnaire demonstrated reliability with a test–retest correlation coefficient of r = 0.85 and an internal consistency (Cronbach's alpha) of 0.71. Convergent validity was established using Spearman correlations with the UHDRS Total Motor Score ( r = 0.75, p < 0.001), Total Maximal Chorea Score ( r = 0.65, p < 0.001), and Total Functional Capacity ( r = 0.53, p < 0.001), in addition to Total Body Sway (TBS, r = 0.62, p < 0.001), a measure of postural stability from the BTrackS™ Balance System. Using ROC curves, the FALL‐HD outperformed (AUC = 0.90) existing measures of balance such as the Total Body Sway (AUC = 0.85), Chair Sit‐to‐Stand Test (AUC = 0.65) and Timed Up and Go (AUC = 0.58). Conclusions: The FALL‐HD is a brief, valid and reliable, screening instrument of fall status, including fall frequency, in ambulatory patients with HD.
- Open Access
- 1 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (11) , 1942-1946
How Early Does Anosognosia Begin in Huntington's Disease?
Background: Individuals with Huntington's disease (HD) commonly experience anosognosia, a lack of awareness of disease‐specific deficits. However, how early anosognosia begins in the course of HD remains unclear. Objective: To characterize the onset of anosognosia in HD by exploring its presence/absence at various stages of disease. Methods: The Anosognosia Scale was given to 60 gene carriers (stratified by the HD Integrated Staging System (HD‐ISS), Total Functional Capacity (TFC), CAG‐Age‐Product (CAP), and composite UHDRS (cUHDRS) score) as well as their study partners. Differences between informant and patient scores of ≥6 points were considered evidence of anosognosia. Results: 18% of participants in HD‐ISS stage 0/1, 22% with TFC = 13, 37% who would be eligible for clinical trials (CAP score 400–500), and 23% with a cUHDRS ≥14 displayed anosognosia. Conclusions: We conclude that anosognosia appears early in HD. This lack of awareness should dissuade against over‐reliance on self‐report instruments in HD clinical research.
- 1 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (11) , 1942-1946
Open AccessHow Early Does Anosognosia Begin in Huntington's Disease?
Background: Individuals with Huntington's disease (HD) commonly experience anosognosia, a lack of awareness of disease‐specific deficits. However, how early anosognosia begins in the course of HD remains unclear. Objective: To characterize the onset of anosognosia in HD by exploring its presence/absence at various stages of disease. Methods: The Anosognosia Scale was given to 60 gene carriers (stratified by the HD Integrated Staging System (HD‐ISS), Total Functional Capacity (TFC), CAG‐Age‐Product (CAP), and composite UHDRS (cUHDRS) score) as well as their study partners. Differences between informant and patient scores of ≥6 points were considered evidence of anosognosia. Results: 18% of participants in HD‐ISS stage 0/1, 22% with TFC = 13, 37% who would be eligible for clinical trials (CAP score 400–500), and 23% with a cUHDRS ≥14 displayed anosognosia. Conclusions: We conclude that anosognosia appears early in HD. This lack of awareness should dissuade against over‐reliance on self‐report instruments in HD clinical research.
- Open Access
- 7 August 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (12) , 2296-2303
Dysphagia in Huntington's Disease: An Evaluation of Swallowing Disturbance across the HD ‐ ISS Staging Spectrum
Background: The onset and pattern of progression of swallowing impairment in HD remain poorly understood. The Swallowing Disturbance Questionnaire (SDQ) has proven useful in assessing dysphagia across various neurological conditions, but its use in HD remains largely unexplored. Objectives: To evaluate swallowing difficulties in HD using the SDQ and Huntington's Disease Integrated Staging System. Methods: The SDQ was administered to 87 gene positive subjects stratified into HD‐ISS Stages 0/1 ( n = 27), 2 ( n = 21), and 3 ( n = 39). Kruskal‐Wallis was used to compare performance among cohorts and partial eta‐squared ( η 2 ) was used to calculate effect sizes. Spearman's rho ( r ) was used to calculate correlations. Results: Total swallowing disturbance score significantly differed across HD‐ISS stages ( ηp 2 = 0.20, p < 0.001), with similar trends and strong effect sizes for both oral ( ηp 2 = 0.15, p < 0.001) and pharyngeal ( ηp 2 = 0.12, p < 0.001) phases. Within cohorts, total swallowing disturbance score was significantly different between Stages 0/1 and 2 ( p = 0.007), Stage 2 and 3 ( p = 0.02) and between Stages 0/1 and 3 ( p < 0.001). Using quartile‐based severity cut‐points (Mild: 0–6, Moderate: 7–14, Severe: >14), 92.6% Stage 0/1 related mild swallowing problems, 7.4% of Stage 0/1 reporting moderate difficulties. In Stage 2, 28.5% described moderate and over 25% reported severe issues. Among Stage 3 subjects, one‐third reported moderate and almost half experienced severe swallowing difficulties. Conclusions: Swallowing disturbances emerge early and progressively worsen across the HD‐ISS staging spectrum, with both oral and pharyngeal phases affected. These findings suggest that early assessment of swallowing function is warranted in HD clinical care.
- 7 August 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (12) , 2296-2303
Open AccessDysphagia in Huntington's Disease: An Evaluation of Swallowing Disturbance across the HD ‐ ISS Staging Spectrum
Background: The onset and pattern of progression of swallowing impairment in HD remain poorly understood. The Swallowing Disturbance Questionnaire (SDQ) has proven useful in assessing dysphagia across various neurological conditions, but its use in HD remains largely unexplored. Objectives: To evaluate swallowing difficulties in HD using the SDQ and Huntington's Disease Integrated Staging System. Methods: The SDQ was administered to 87 gene positive subjects stratified into HD‐ISS Stages 0/1 ( n = 27), 2 ( n = 21), and 3 ( n = 39). Kruskal‐Wallis was used to compare performance among cohorts and partial eta‐squared ( η 2 ) was used to calculate effect sizes. Spearman's rho ( r ) was used to calculate correlations. Results: Total swallowing disturbance score significantly differed across HD‐ISS stages ( ηp 2 = 0.20, p < 0.001), with similar trends and strong effect sizes for both oral ( ηp 2 = 0.15, p < 0.001) and pharyngeal ( ηp 2 = 0.12, p < 0.001) phases. Within cohorts, total swallowing disturbance score was significantly different between Stages 0/1 and 2 ( p = 0.007), Stage 2 and 3 ( p = 0.02) and between Stages 0/1 and 3 ( p < 0.001). Using quartile‐based severity cut‐points (Mild: 0–6, Moderate: 7–14, Severe: >14), 92.6% Stage 0/1 related mild swallowing problems, 7.4% of Stage 0/1 reporting moderate difficulties. In Stage 2, 28.5% described moderate and over 25% reported severe issues. Among Stage 3 subjects, one‐third reported moderate and almost half experienced severe swallowing difficulties. Conclusions: Swallowing disturbances emerge early and progressively worsen across the HD‐ISS staging spectrum, with both oral and pharyngeal phases affected. These findings suggest that early assessment of swallowing function is warranted in HD clinical care.
- Open Access
- 18 July 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1191718
LASSI-L detects early cognitive changes in pre-motor manifest Huntington’s disease: a replication and validation study
Background and objectives: Cognitive decline is an important early sign in pre-motor manifest Huntington’s disease (preHD) and is characterized by deficits across multiple domains including executive function, psychomotor processing speed, and memory retrieval. Prior work suggested that the Loewenstein-Acevedo Scale for Semantic Interference and Learning (LASSI-L)–a verbal learning task that simultaneously targets these domains - could capture early cognitive changes in preHD. The current study aimed to replicate, validate and further analyze the LASSI-L in preHD using larger datasets.Methods: LASSI-L was administered to 50 participants (25 preHD and 25 Healthy Controls) matched for age, education, and sex in a longitudinal study of disease progression and compared to performance on MMSE, Trail A & B, SCWT, SDMT, Semantic Fluency (Animals), and CVLT-II. Performance was then compared to a separate age-education matched-cohort of 25 preHD participants. Receiver operating curve (ROC) and practice effects (12 month interval) were investigated. Group comparisons were repeated using a preHD subgroup restricted to participants predicted to be far from diagnosis (Far subgroup), based on CAG-Age-Product scaled (CAPs) score. Construct validity was assessed through correlations with previously established measures of subcortical atrophy.Results: PreHD performance on all sections of the LASSI-L was significantly different from controls. The proactive semantic interference section (PSI) was sensitive (p = 0.0001, d = 1.548), similar across preHD datasets (p = 1.0), reliable on test–retest over 12 months (spearman rho = 0.88; p = p = 0.03). The number of intrusions on PSI was negatively correlated with caudate volume.Discussion: The LASSI-L is a sensitive, reliable, efficient tool for detecting cognitive decline in preHD. By using a unique verbal learning test paradigm that simultaneously targets executive function, processing speed and memory retrieval, the LASSI-L outperforms many other established tests and captures early signs of cognitive impairment. With further longitudinal validation, the LASSI-L could prove to be a useful biomarker for clinical research in preHD.
- 18 July 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1191718
Open AccessLASSI-L detects early cognitive changes in pre-motor manifest Huntington’s disease: a replication and validation study
Background and objectives: Cognitive decline is an important early sign in pre-motor manifest Huntington’s disease (preHD) and is characterized by deficits across multiple domains including executive function, psychomotor processing speed, and memory retrieval. Prior work suggested that the Loewenstein-Acevedo Scale for Semantic Interference and Learning (LASSI-L)–a verbal learning task that simultaneously targets these domains - could capture early cognitive changes in preHD. The current study aimed to replicate, validate and further analyze the LASSI-L in preHD using larger datasets.Methods: LASSI-L was administered to 50 participants (25 preHD and 25 Healthy Controls) matched for age, education, and sex in a longitudinal study of disease progression and compared to performance on MMSE, Trail A & B, SCWT, SDMT, Semantic Fluency (Animals), and CVLT-II. Performance was then compared to a separate age-education matched-cohort of 25 preHD participants. Receiver operating curve (ROC) and practice effects (12 month interval) were investigated. Group comparisons were repeated using a preHD subgroup restricted to participants predicted to be far from diagnosis (Far subgroup), based on CAG-Age-Product scaled (CAPs) score. Construct validity was assessed through correlations with previously established measures of subcortical atrophy.Results: PreHD performance on all sections of the LASSI-L was significantly different from controls. The proactive semantic interference section (PSI) was sensitive (p = 0.0001, d = 1.548), similar across preHD datasets (p = 1.0), reliable on test–retest over 12 months (spearman rho = 0.88; p = p = 0.03). The number of intrusions on PSI was negatively correlated with caudate volume.Discussion: The LASSI-L is a sensitive, reliable, efficient tool for detecting cognitive decline in preHD. By using a unique verbal learning test paradigm that simultaneously targets executive function, processing speed and memory retrieval, the LASSI-L outperforms many other established tests and captures early signs of cognitive impairment. With further longitudinal validation, the LASSI-L could prove to be a useful biomarker for clinical research in preHD.
- Open Access
- 19 August 2022
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- Vol. 31 (6) , 1163-1168
Source recognition discriminability impairment in Huntington’s versus Alzheimer’s disease: Evidence from the CVLT-3
Research suggests that individuals with Huntington’s disease (HD) perform better than individuals with Alzheimer’s disease (AD) on the California Verbal Learning Test (CVLT) Yes/No Recognition trial. However, those with HD have been shown to have deficits comparable to those with AD on the Source Recognition Discriminability (RD) index (which assesses the ability to distinguish between List A targets and List B distractors), suggesting that HD may involve selective impairment in aspects of yes/no recognition that rely on source memory. However, whether individuals with HD and AD show comparable deficits on Source RD across stages of dementia severity has not been adequately investigated. We examined performance on the CVLT-3 List A vs. List B RD index in individuals with HD or AD and mild or moderate dementia. Among individuals with mild dementia, scores were higher in the HD versus AD group, whereas among individuals with moderate dementia, scores were comparable between the HD and AD groups; this corresponded to differential performance across dementia stages among individuals with HD, but not AD. The present findings suggest that, relative to AD, HD may be associated with disproportionate decline in aspects of yes/no recognition that rely on source memory.
- 19 August 2022
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- Vol. 31 (6) , 1163-1168
Open AccessSource recognition discriminability impairment in Huntington’s versus Alzheimer’s disease: Evidence from the CVLT-3
Research suggests that individuals with Huntington’s disease (HD) perform better than individuals with Alzheimer’s disease (AD) on the California Verbal Learning Test (CVLT) Yes/No Recognition trial. However, those with HD have been shown to have deficits comparable to those with AD on the Source Recognition Discriminability (RD) index (which assesses the ability to distinguish between List A targets and List B distractors), suggesting that HD may involve selective impairment in aspects of yes/no recognition that rely on source memory. However, whether individuals with HD and AD show comparable deficits on Source RD across stages of dementia severity has not been adequately investigated. We examined performance on the CVLT-3 List A vs. List B RD index in individuals with HD or AD and mild or moderate dementia. Among individuals with mild dementia, scores were higher in the HD versus AD group, whereas among individuals with moderate dementia, scores were comparable between the HD and AD groups; this corresponded to differential performance across dementia stages among individuals with HD, but not AD. The present findings suggest that, relative to AD, HD may be associated with disproportionate decline in aspects of yes/no recognition that rely on source memory.
- 14 March 2022
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 103, 115-118
Differences in body sway can be identified in Huntington's disease using a practical balance assessment device
- 14 March 2022
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 103, 115-118
Differences in body sway can be identified in Huntington's disease using a practical balance assessment device
- Open Access
- 28 April 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 87, 32-38
Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression
- 28 April 2021
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 87, 32-38
Open AccessPlasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression
- Open Access
- 18 February 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (5) , 868-874
Inversion Recovery Ultrashort TE MR Imaging of Myelin is Significantly Correlated with Disability in Patients with Multiple Sclerosis
Circulating extracellular vesicles (EVs) present in the bodily fluids of patients with cancer may provide non-invasive access to the tumor tissue. Yet, the transcriptomic lineage of tumor-derived EVs before and after tumor-resection remains poorly understood. Here, we established 60 total small RNA-sequencing profiles from 17 aggressive prostate cancer (PCa) patient’s tumor and adjacent normal tissue, and EVs isolated from urine, serum, and cancer cell culture media. We interrogated the key satellite alteration in tumor-derived EVs and found that resection of tumor prostate tissue leads to differential expression of reactive oxygen species (ROS), P53 pathways, inflammatory/cytokines, oncogenes, and tumor suppressor genes in the EV nanosatellites. Furthermore, we provide a set of novel EV-specific RNA signature, which are present in cancer but are nonexistent in post-resection patients with undetectable cancer. Finally, using a de novo RNAseq assembly followed by characterization of the small RNA landscape, we found novel small RNA clusters (smRCs) in the EVs, which reside in the unannotated regions. Novel smRCs were orthogonally validated for their differential expression in the ‘biomarker discovery’ cohort using RT-qPCR. We demonstrate that circulating tumor EVs provide a glimpse of the tumor tissue biology, resolving a major bottleneck in the current liquid biopsy efforts. Secretory vesicles appear to be playing a key role in non-canonical Wnt signaling and miRNA pathways, similar to the circulating tumor cells (CTCs), hence, we propose that such vesicles be called circulating tumor extracellular vesicles (CTEVs).
- 18 February 2021
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 42 (5) , 868-874
Open AccessInversion Recovery Ultrashort TE MR Imaging of Myelin is Significantly Correlated with Disability in Patients with Multiple Sclerosis
Circulating extracellular vesicles (EVs) present in the bodily fluids of patients with cancer may provide non-invasive access to the tumor tissue. Yet, the transcriptomic lineage of tumor-derived EVs before and after tumor-resection remains poorly understood. Here, we established 60 total small RNA-sequencing profiles from 17 aggressive prostate cancer (PCa) patient’s tumor and adjacent normal tissue, and EVs isolated from urine, serum, and cancer cell culture media. We interrogated the key satellite alteration in tumor-derived EVs and found that resection of tumor prostate tissue leads to differential expression of reactive oxygen species (ROS), P53 pathways, inflammatory/cytokines, oncogenes, and tumor suppressor genes in the EV nanosatellites. Furthermore, we provide a set of novel EV-specific RNA signature, which are present in cancer but are nonexistent in post-resection patients with undetectable cancer. Finally, using a de novo RNAseq assembly followed by characterization of the small RNA landscape, we found novel small RNA clusters (smRCs) in the EVs, which reside in the unannotated regions. Novel smRCs were orthogonally validated for their differential expression in the ‘biomarker discovery’ cohort using RT-qPCR. We demonstrate that circulating tumor EVs provide a glimpse of the tumor tissue biology, resolving a major bottleneck in the current liquid biopsy efforts. Secretory vesicles appear to be playing a key role in non-canonical Wnt signaling and miRNA pathways, similar to the circulating tumor cells (CTCs), hence, we propose that such vesicles be called circulating tumor extracellular vesicles (CTEVs).
- 22 November 2020
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 8 (1) , 100-105
Central Cognitive Processing Speed Is an Early Marker of Huntington's Disease Onset
Background: Several studies have suggested that cognitive processing speed may be useful for assessing early cognitive change in premanifest Huntington's disease (HD); however, current measures lack the ability to control for the effects of motor dysfunction commonly found in HD. The Computerized Test of Information Processing (CTiP) is a rapidly administered computerized tool that allows for the examination of central cognitive processing speed by using motor‐corrected scores to account for motor dysfunction.Objective: To examine central cognitive processing speed as an early marker of HD onset using the CTiP.Methods: The CTiP and other measures were administered to 102 HD gene carriers and 55 healthy adults (HA). Gene carriers included presymptomatic HD (pre‐HD; n = 33), prodromal HD (pro‐HD; ie, individuals close to disease onset; n = 23), and mild–moderate HD (HD; n = 46).Results: The HD group performed significantly slower than all other groups (HA, pre‐HD, and pro‐HD) on most subtests (Ps < .05). Moreover, the pro‐HD group performed significantly slower than the HA group on both motor‐corrected subtests (Ps < 0.05). Effect sizes associated with significant group differences between the pro‐HD and HA groups on motor‐corrected CTiP subtests (d = 0.73 and 0.84) were similar to effect sizes associated with group differences on the Symbol Digit Modalities Test (d = .82) and other traditional cognitive assessments (Montreal Cognitive Assessment, d = .75; Mini‐Mental State Examination, d = .84).Conclusions: The CTiP may be a useful marker of deficits in central cognitive processing speed in individuals close to manifest onset of HD.
- 22 November 2020
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 8 (1) , 100-105
Central Cognitive Processing Speed Is an Early Marker of Huntington's Disease Onset
Background: Several studies have suggested that cognitive processing speed may be useful for assessing early cognitive change in premanifest Huntington's disease (HD); however, current measures lack the ability to control for the effects of motor dysfunction commonly found in HD. The Computerized Test of Information Processing (CTiP) is a rapidly administered computerized tool that allows for the examination of central cognitive processing speed by using motor‐corrected scores to account for motor dysfunction.Objective: To examine central cognitive processing speed as an early marker of HD onset using the CTiP.Methods: The CTiP and other measures were administered to 102 HD gene carriers and 55 healthy adults (HA). Gene carriers included presymptomatic HD (pre‐HD; n = 33), prodromal HD (pro‐HD; ie, individuals close to disease onset; n = 23), and mild–moderate HD (HD; n = 46).Results: The HD group performed significantly slower than all other groups (HA, pre‐HD, and pro‐HD) on most subtests (Ps < .05). Moreover, the pro‐HD group performed significantly slower than the HA group on both motor‐corrected subtests (Ps < 0.05). Effect sizes associated with significant group differences between the pro‐HD and HA groups on motor‐corrected CTiP subtests (d = 0.73 and 0.84) were similar to effect sizes associated with group differences on the Symbol Digit Modalities Test (d = .82) and other traditional cognitive assessments (Montreal Cognitive Assessment, d = .75; Mini‐Mental State Examination, d = .84).Conclusions: The CTiP may be a useful marker of deficits in central cognitive processing speed in individuals close to manifest onset of HD.